Browsing by Author "Kaye, Jeffrey"

Now showing 1 - 2 of 2
  • Thumbnail Image
    Item
    Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease
    (Alzheimer's & dementia, 2011-05-14) Sperling, Reisa A.; Bennett, David A.; Iwatsubo, Takeshi; Kaye, Jeffrey; Montine, Thomas J.; Yaffe, Kristine; Phelps, Creighton H.
    The pathophysiological process of Alzheimer’s disease (AD) is thought to begin many years before the diagnosis of AD dementia. This long “preclinical” phase of AD would provide a critical opportunity for therapeutic intervention; however, we need to further elucidate the link between the pathological cascade of AD and the emergence of clinical symptoms. The National Institute on Aging and the Alzheimer’s Association convened an international workgroup to review the biomarker, epidemiological, and neuropsychological evidence, and to develop recommendations to determine the factors which best predict the risk of progression from “normal” cognition to mild cognitive impairment and AD dementia. We propose a conceptual framework and operational research criteria, based on the prevailing scientific evidence to date, to test and refine these models with longitudinal clinical research studies. These recommendations are solely intended for research purposes and do not have any clinical implications at this time. It is hoped that these recommendations will provide a common rubric to advance the study of preclinical AD, and ultimately, aid the field in moving toward earlier intervention at a stage of AD when some disease-modifying therapies may be most efficacious.
  • Thumbnail Image
    Item
    Vitamin E and Donepezil for the Treatment of Mild Cognitive Impairment
    (New England Journal of Medicine, 2005-04-13) Petersen, Ronald C.; Thomas, Ronald G.; Kaye, Jeffrey; Sano, Mary
    Mild cognitive impairment is a transitional state between the cognitive changes of normal aging and early Alzheimer’s disease. In a double-blind study, we evaluated subjects with the amnestic subtype of mild cognitive impairment. Subjects were randomly assigned to receive 2000 IU of vitamin E daily, 10 mg of donepezil daily, or placebo for three years. The primary outcome was clinically possible or probable Alzheimer’s disease; secondary outcomes were cognition and function.